@article{oai:nagoya.repo.nii.ac.jp:00013451,
 author = {KAWABE, TSUTOMU and MATSUSHIMA, MIYOKO and HASHIMOTO, NAOZUMI and IMAIZUMI, KAZUYOSHI and HASEGAWA, YOSHINORI},
 issue = {3-4},
 journal = {Nagoya Journal of Medical Science},
 month = {Aug},
 note = {The CD40 ligand/CD40 pathway is widely recognized for its prominent role in immune regulation and homeostasis. CD40, a member of the tumor necrosis factor receptor family, is expressed by antigenpresenting cells, as well as non-immune cells and tumors. The engagement of the CD40 and CD40 ligands, which are transiently expressed on T cells and other non-immune cells under inflammatory conditions, regulates a wide spectrum of molecular and cellular processes, including the initiation and progression of cellular and humoral adaptive immunity. Based on recent research findings, the engagement of the CD40 with a deregulated amount of CD40 ligand has been implicated in a number of inflammatory diseases. We will discuss the involvement of the CD40 ligand/CD40 interaction in the pathophysiology of inflammatory diseases, including autoimmune diseases, atherothrombosis, cancer, and respiratory diseases.},
 pages = {69--78},
 title = {CD40/CD40 LIGAND INTERACTIONS IN IMMUNE RESPONSES AND PULMONARY IMMUNITY},
 volume = {73},
 year = {2011}
}